Read by QxMD icon Read

diagnosis hepatic steatosis

T Mahévas, D Gobert, M Gatfossé, A Mekinian, O Fain
INTRODUCTION: Hepatic glycogenosis is a rare syndrome, which includes poorly controlled diabetes mellitus, hepatomegaly, delayed puberty, and growth delay. Insulin edema is sometimes associated. CASE REPORT: An 18-year-old woman presented with diffuse edema, hepatomegaly, amenorrhea, uncontrolled diabetes, and elevated transaminases and cholestasis. Hepatic ultrasonography and abdominal computed tomographic scan confirmed the hepatomegaly. The liver biopsy showed a massive glycogenosis and the diagnosis of hepatic glycogenosis was confirmed...
October 13, 2016: La Revue de Médecine Interne
J E Nelson, P Handa, B Aouizerat, L Wilson, L A Vemulakonda, M M Yeh, K V Kowdley
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a complex, multifactorial disease affected by diet, lifestyle and genetics. Proinflammatory cytokines like IL-1β and IL-6 have been shown to be elevated in non-alcoholic steatohepatitis (NASH). AIM: To investigate the relationship between IL1B and IL6 gene polymorphisms and histological features of NAFLD in the NASH CRN cohort. METHODS: A total of 604 adult (≥18 years) non-Hispanic Caucasians with biopsy-proven NAFLD were genotyped for the following SNPs: IL1B, rs16944, rs1143634; IL6, rs1800795, rs10499563...
October 11, 2016: Alimentary Pharmacology & Therapeutics
M Maida, F S Macaluso, F Salomone, S Petta
NAFLD (Non-Alcoholic Fatty Liver Disease) is an increasingly significant public health issue, regarded as the most relevant liver disease of the twenty-first century. Approximately 20%-30% of NAFLD subjects develop a NASH (Non-Alcoholic Steato-Hepatitis), a condition which can potentially evolve to liver cirrhosis and hepatocellular carcinoma. For these reasons a proper evaluation of liver damage is a key point for diagnosis and prognosis and liver biopsy still remains the "gold standard" procedure both for discrimination between steatosis and steatohepatitis and assessment of the degree of liver fibrosis...
October 4, 2016: Current Molecular Medicine
Sasha van Katwyk, Doug Coyle, Curtis Cooper, Kusala Pussegoda, Chris Cameron, Becky Skidmore, Stacey Brener, David Moher, Kednapa Thavorn
BACKGROUND: Liver biopsy remains the gold standard for the diagnosis of liver fibrosis, but its use as a diagnostic tool is limited by its invasive nature and high cost. OBJECTIVE: To systematically review the cost-effectiveness of transient elastography (TE) with and without controlled attenuation parameter (CAP) for the diagnosis of liver fibrosis or steatosis in patients with hepatitis B, hepatitis C, alcoholic liver disease, and non-alcoholic fatty liver disease...
October 3, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
S Guth, E Windler, U Leise, C M Bamberger
No abstract text is available yet for this article.
March 2016: Ultrasound Int Open
Teresa Auguet, Gemma Aragonès, Alba Berlanga, Esther Guiu-Jurado, Andreu Martí, Salomé Martínez, Fàtima Sabench, Mercé Hernández, Carmen Aguilar, Joan Josep Sirvent, Daniel Del Castillo, Cristóbal Richart
Specific miRNA expression profiles have been shown to be associated with nonalcoholic fatty liver disease (NAFLD). We examined the correlation between the circulating levels and hepatic expression of miR122 and miR33a/b*, the key lipid metabolism-related gene expression and the clinicopathological factors of obese women with NAFLD. We measured miR122 and miR33a/b* expression in liver samples from 62 morbidly obese (MO), 30 moderately obese (ModO), and eight normal-weight controls. MiR122 and miR33a/b* expression was analyzed by qRT-PCR...
2016: International Journal of Molecular Sciences
Titilola Osawaye Olusanya, Olufunmilayo Adenike Lesi, Adekunle Ayokunle Adeyomoye, Olufemi Adetola Fasanmade
INTRODUCTION: Worldwide, Non-alcoholic fatty liver disease (NAFLD) has become an important cause of chronic liver disease and cardiovascular morbidity, even more so in subjects with Type II Diabetes Mellitus (T2DM). The aim of this study was to determine the prevalence and risk factors of NAFLD in an African population with Type II Diabetes Mellitus. METHODS: We performed a case control study and evaluated anthropometric and biochemical risk factors for NAFLD in 336 subjects (T2DM and non-diabetic controls)...
2016: Pan African Medical Journal
Yuichi Nozaki, Noriko Sato, Tsuyoshi Tajima, Kanehiro Hasuo, Yasushi Kojima, Kumiko Umemoto, Saori Mishima, Shintaro Mikami, Tomohiro Nakayama, Toru Igari, Junichi Akiyama, Masatoshi Imamura, Naohiko Masaki, Mikio Yanase
The ratio of the number of patients with non-alcoholic steatohepatitis (NASH) to the total number of patients with liver dysfunction has increased in many countries around the world. Liver dysfunction is also caused by multiple blood transfusions in patients with leukemia and other hematological diseases, with liver dysfunction often accompanied by secondary hemochromatosis. This study describes a 25-year-old man with secondary hemochromatosis combined with NASH. Magnetic resonance imaging was useful for visualizing the distributions of both iron and fat in the liver of this patient in order to make a differential diagnosis and to evaluate the effect of treatment...
2016: Internal Medicine
Cher Heng Tan, Sudhakar Kundapur Venkatesh
Recent advances in the noninvasive imaging of chronic liver disease have led to improvements in diagnosis, particularly with magnetic resonance imaging (MRI). A comprehensive evaluation of the liver may be performed with the quantification of the degree of hepatic steatosis, liver iron concentration, and liver fibrosis. In addition, MRI of the liver may be used to identify complications of cirrhosis, including portal hypertension, ascites, and the development of hepatocellular carcinoma. In this review article, we discuss the state of the art techniques in liver MRI, namely, magnetic resonance elastography, hepatobiliary phase MRI, and liver fat and iron quantification MRI...
September 15, 2016: Gut and Liver
M Munteanu, D Tiniakos, Q Anstee, F Charlotte, G Marchesini, E Bugianesi, M Trauner, M Romero Gomez, C Oliveira, C Day, J-F Dufour, S Bellentani, Y Ngo, S Traussnig, H Perazzo, O Deckmyn, P Bedossa, V Ratziu, T Poynard
BACKGROUND: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. AIMS: To improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading. METHODS: We pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium...
October 2016: Alimentary Pharmacology & Therapeutics
Nimantha M W de Alwis, Quentin M Anstee, Christopher P Day
Patients with nonalcoholic fatty liver disease (NAFLD) are asymptomatic and present with either unexplained abnormal liver blood tests or a bright liver on ultrasonography. Some patients will have normal liver blood tests raising the issue of whether patients with risk factors for NAFLD (diabetes and/or metabolic syndrome [MS]) should be screened for its presence with biomarkers, such as the fatty liver index (FLI). The diagnosis of NAFLD requires the exclusion of other causes of chronic liver disease and steatosis, especially heavy alcohol consumption and viral hepatitis particularly HCV genotype 3...
2016: Digestive Diseases
Valentina Peta, Djamel Elaribi, Ludovico Abenavoli
Alcohol is considered one of the most common hepatotoxin, and chronic alcoholic liver disease is affecting millions of subjects worldwide. The three most frequently manifestations of alcoholic liver disease are steatosis, acute alcoholic hepatitis and liver cirrhosis. The diagnosis of Alcoholic Liver Diseases (ALD) is made by clinical and laboratory analysis. Actually do not exist a single laboratory test able to confirm the diagnosis of ALD, but in the last years several serum markers and laboratory abnormalities have been discovered in these patients...
2016: Reviews on Recent Clinical Trials
Zehra Karacaer, Gokcan Okur, Hakan Cermik, Demet Altun
OBJECTIVES: Our aim was to investigate the association of liver fibrosis and necroinflammation with HS in untreated young patients with chronic hepatitis B (CHB). MATERIALS AND METHODS: A retrospective study was conducted in a military hospital in Turkey. A total of 254 subjects with CHB were included in this study. These subjects were divided into two groups: group 1 consisted of patients with hepatic steatosis (HS) according to ultrasonography (USG) and group 2 consisted of non-HS subjects...
September 2016: Postgraduate Medicine
Pegah Golabi, Cameron T Locklear, Patrick Austin, Sophie Afdhal, Melinda Byrns, Lynn Gerber, Zobair M Younossi
AIM: To investigate the efficacy of exercise interventions on hepatic fat mobilization in non-alcoholic fatty liver disease (NAFLD) patients. METHODS: Ovid-Medline, PubMed, EMBASE and Cochrane database were searched for randomized trials and prospective cohort studies in adults aged ≥ 18 which investigated the effects of at least 8 wk of exercise only or combination with diet on NAFLD from 2010 to 2016. The search terms used to identify articles, in which exercise was clearly described by type, duration, intensity and frequency were: "NASH", "NAFLD", "non-alcoholic steatohepatitis", "non-alcoholic fatty liver disease", "fat", "steatosis", "diet", "exercise", "MR spectroscopy" and "liver biopsy"...
July 21, 2016: World Journal of Gastroenterology: WJG
Ludovico Abenavoli, Mario Masarone, Alessandro Federico, Valerio Rosato, Marcello Dallio, Carmela Loguercio, Marcello Persico
Alcohol represents the oldest substance of abuse known and Alcoholic Liver Disease (ALD) is the most common cause of chronic liver disease worldwide. The ALD includes a wide spectrum of injury and may lead progressively from simple steatosis to frank cirrhosis. The ALD diagnosis may be hard and it is mainly defined by the history of chronic alcohol intake, physical and laboratory abnormalities suggestive of liver disease. Abstinence is the cornerstone of ALD therapy. Although the burden on health of ALD is not negligible, in the last decades few therapeutic advances have been made...
2016: Reviews on Recent Clinical Trials
Sarmad Said, Debabrata Mukherjee, Thomas F Whayne
Cardiovascular (CV) disease is the most common cause of morbidity and mortality worldwide, particularly in the presence of the metabolic syndrome (MetS). Classifications and treatment of the MetS have recently been redefined. While the majority of the cardiac components such as hypertension, diabetes mellitus (DM) and dyslipidemia are objectively measurable elements, a few disparities among the definitions have to be considered that can variably modify diagnosis, treatment and prevention. Noncardiac factors such as liver disease (including, but not limited to, alcoholic and non-alcoholic steatosis/hepatitis), renal disease, severe obesity, polycystic ovarian syndrome and obstructive sleep apnea, may have independent or synergistic relationship with complementary cardiac MetS elements, and these additional risk factors may have an incremental adverse impact on CV outcome...
July 22, 2016: Current Vascular Pharmacology
Manuele Gori, Maria Chiara Simonelli, Sara Maria Giannitelli, Luca Businaro, Marcella Trombetta, Alberto Rainer
BACKGROUND AND AIM: Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease worldwide, ranging from simple steatosis to nonalcoholic steatohepatitis, which may progress to cirrhosis, eventually leading to hepatocellular carcinoma (HCC). HCC ranks as the third highest cause of cancer-related death globally, requiring an early diagnosis of NAFLD as a potential risk factor. However, the molecular mechanisms underlying NAFLD are still under investigation. So far, many in vitro studies on NAFLD have been hampered by the limitations of 2D culture systems, in which cells rapidly lose tissue-specific functions...
2016: PloS One
Fabio Conti, Carla Serra, Ranka Vukotic, Erica Fiorini, Cristina Felicani, Elena Mazzotta, Antonietta D'Errico, Gabriella Verucchi, Marco Lenzi, Pietro Andreone
BACKGROUND & AIMS: Elastography point quantification (ElastPQ) is a novel noninvasive method for the assessment of liver fibrosis by measuring liver stiffness. The aim of this study was to evaluate the accuracy of ElastPQ for the diagnosis of liver fibrosis and to assess impact of steatosis on liver stiffness measurement (LSM), in a cohort of patients with chronic hepatitis C (CHC). METHODS: In this single-center cross-sectional study, 211 consecutive patients with CHC, scheduled for liver biopsy, were examined with the ElastPQ technology...
July 1, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
G Lui, V W-S Wong, G L-H Wong, W C-W Chu, C-K Wong, I M H Yung, R Y K Wong, S-L Yeung, D K-W Yeung, C S K Cheung, H-Y Chan, H L-Y Chan, N Lee
BACKGROUND: Little is known about the importance of liver fibrosis and fatty liver in HIV-monoinfected individuals without hepatitis virus co-infection, particularly among the Asian population. AIM: To evaluate prevalence and risk factors for liver fibrosis and fatty liver in Asian HIV-monoinfected individuals. METHODS: Eighty asymptomatic HIV-monoinfected individuals (tested negative for HBV/HCV) were compared with 160 matched HIV-uninfected healthy controls...
August 2016: Alimentary Pharmacology & Therapeutics
Maurizio Loy, Giancarlo Serra, Luchino Chessa
PURPOSE: To evaluate the prevalence of bright liver echo pattern (BLP) on ultrasonography and its correlation with liver steatosis (LS), and fibrosis in patients with chronic hepatitis C. The usefulness of detecting skip areas for steatosis diagnosis has also been evaluated. METHODS: The study included 88 patients with chronic hepatitis C (55 men, 33 women, average age 45.7 ± 11.2 years). Ultrasound examination was performed in all patients before liver biopsy...
2016: Journal of Ultrasound
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"